{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(11)"],"submitter":["Ritchie DS"],"pubmed_abstract":["In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total T cells, of which 14-38% expressed the CAR. Grade 3 or 4 toxicity was not observed. One patient achieved a cytogenetic remission whereas another with active leukemia had a reduction in peripheral blood (PB) blasts and a third showed a protracted remission. Using an aliquot of In111-labeled CAR T cells, we demonstrated trafficking to the bone marrow (BM) in those patients with the greatest clinical benefit. Furthermore, in a patient with leukemia cutis, CAR T cells infiltrated proven sites of"],"journal":["Molecular therapy : the journal of the American Society of Gene Therapy"],"pagination":["2122-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3831035"],"repository":["biostudies-literature"],"pubmed_title":["Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia."],"pmcid":["PMC3831035"],"pubmed_authors":["Peinert S","Scott AM","Honemann D","Chen K","Kravets L","Kershaw MH","Ritchie DS","Neeson PJ","Westwood JA","Khot A","Shin M","Trapani JA","Tainton K","Darcy PK","Prince HM","Dickinson M","Gambell P","Wall DM","Tai T","Westerman DA","Haurat J","Smyth MJ"],"additional_accession":[]},"is_claimable":false,"name":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.","description":"In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total T cells, of which 14-38% expressed the CAR. Grade 3 or 4 toxicity was not observed. One patient achieved a cytogenetic remission whereas another with active leukemia had a reduction in peripheral blood (PB) blasts and a third showed a protracted remission. Using an aliquot of In111-labeled CAR T cells, we demonstrated trafficking to the bone marrow (BM) in those patients with the greatest clinical benefit. Furthermore, in a patient with leukemia cutis, CAR T cells infiltrated proven sites of","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Nov","modification":"2026-05-07T01:34:03.793Z","creation":"2026-04-07T22:27:53.393Z"},"accession":"S-EPMC3831035","cross_references":{"pubmed":["23831595"],"doi":["10.1038/mt.2013.154"]}}